Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/7/2018 |
| Start Date: | December 2009 |
| End Date: | December 2020 |
| Contact: | Irene Ghobrial, MD |
| Email: | irene_ghobrial@dfci.harvard.edu |
| Phone: | 617-632-4198 |
Medical Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
The purpose of this study is to obtain bone marrow and peripheral blood samples, along with
clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM),
Smoldering MM, and other lymphoplasmacytic lymphomas (LPL) including but not limited to MGUS
and IgG or IgA LPL. These samples will become part of a tissue bank and will be used in
ongoing studies to find out more about the causes and biology of MM, WM and LPL; to identify
what factors result in normal cells becoming cancer; to determine how to improve treatment
options; to study how the immune system identifies abnormal cells; and to evaluate the immune
function in these diseases. The investigators will also study the tumor cells at the level of
the participant's genes to develop treatment strategies as well as to better understand how
biologic differences affect patient outcomes.
clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM),
Smoldering MM, and other lymphoplasmacytic lymphomas (LPL) including but not limited to MGUS
and IgG or IgA LPL. These samples will become part of a tissue bank and will be used in
ongoing studies to find out more about the causes and biology of MM, WM and LPL; to identify
what factors result in normal cells becoming cancer; to determine how to improve treatment
options; to study how the immune system identifies abnormal cells; and to evaluate the immune
function in these diseases. The investigators will also study the tumor cells at the level of
the participant's genes to develop treatment strategies as well as to better understand how
biologic differences affect patient outcomes.
- Participants will be asked to complete a medical survey which includes demographics,
diagnosis, and treatment history, medical history, lab results and symptoms experienced.
- Participants will then receive instructions for the tissue banking procedure, which
involves donating bone marrow and blood samples. These will be collected only at times
when necessary clinical bone marrow samples are obtained and will not require an extra
visit to the doctor.
- The investigators are also requesting permission to collect medical information from the
participant's record and link this information to the specimens so that we may better
understand the participant's response to treatment. For samples obtained prior to
beginning therapy, this information might allow us to develop new ways of predicting
response to therapy. The investigators are also requesting permission to store samples
of blood and bone marrow to establish a tissue bank for future research to these
diseases. These samples will be de-identified; any of the participant's personal health
information identifiers will be removed.
- The tumor sample may be obtained at diagnosis, during treatment and/or as the time of
relapse. The timing of sample collection will coincide with other bone marrow tests
required to assess the response to therapy or any other clinical purpose.
diagnosis, and treatment history, medical history, lab results and symptoms experienced.
- Participants will then receive instructions for the tissue banking procedure, which
involves donating bone marrow and blood samples. These will be collected only at times
when necessary clinical bone marrow samples are obtained and will not require an extra
visit to the doctor.
- The investigators are also requesting permission to collect medical information from the
participant's record and link this information to the specimens so that we may better
understand the participant's response to treatment. For samples obtained prior to
beginning therapy, this information might allow us to develop new ways of predicting
response to therapy. The investigators are also requesting permission to store samples
of blood and bone marrow to establish a tissue bank for future research to these
diseases. These samples will be de-identified; any of the participant's personal health
information identifiers will be removed.
- The tumor sample may be obtained at diagnosis, during treatment and/or as the time of
relapse. The timing of sample collection will coincide with other bone marrow tests
required to assess the response to therapy or any other clinical purpose.
Inclusion Criteria:
- Any individual diagnosed with Multiple Myeloma, Waldenstrom Macroglobulinemia, MGUS,
smoldering MM or other lymphoplasmacytic lymphomas
- Signed informed consent
- 18 years of age or older
We found this trial at
1
site
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
